top of page
Transforming gene therapy with an advanced AAV delivery platform
Enhanced specificity and accelerated development through modular, post-manufacture enzymatic AAV vector modification.
We are developing an innovative technology that equips AAV vectors with molecules to accurately target the intended tissues.
Efficient delivery of recombinant AAV vector cargo to the right cells remains a key challenge for successful gene therapies.
​
Our platform technology enables more efficient delivery and thus can help reduce unintended side effects.
TAVIRA THERAPEUTICS WAS CO-FOUNDED BY
Els Henckaerts, MD PhD
Benjamien Moeyaert, PhD
Veronick Benoy, PhD
Vibha Kiran Tamboli, PhD
Inge Van Hove, PhD
INVESTORS
bottom of page